Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Basik

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Proteomics. Clinical Applications|July 10, 2020
Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer CellsBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
The Analyst|September 29, 2021
A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissuesBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
3D chromatin remodeling potentiates transcriptional programs driving cell invasionBenjamin Lebeau, Maïka Jangal, Tiejun Zhao, et al.
Cell Reports|May 3, 2018
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer ProgressionMarie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, et al.
Cell Reports|December 15, 2023
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer ProgressionMarie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2026
Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial resultsTalia Roseshter, Anna Klemantovich, Josiane Lafleur, et al.
Cancer Research Communications|April 13, 2026
ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastropheJuliet Guay, Hellen Kuasne, Catherine Chabot, et al.
Cell Metabolism|September 15, 2015
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast CancerFanny Dupuy, Sébastien Tabariès, Sylvia Andrzejewski, et al.
NAR Cancer|October 9, 2025
Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatmentNouritza Torossian, Marc Gabriel, Panagiotis Papoutsoglou, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Proteomics. Clinical Applications|July 10, 2020
Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer CellsBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
The Analyst|September 29, 2021
A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissuesBjoern C Froehlich, Robert Popp, Constance A Sobsey, et al.
International Journal of Molecular Sciences|April 23, 2022
A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue SpecimensGeorgia Mitsa, Qianyu Guo, Christophe Goncalves, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
3D chromatin remodeling potentiates transcriptional programs driving cell invasionBenjamin Lebeau, Maïka Jangal, Tiejun Zhao, et al.
Cell Reports|May 3, 2018
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer ProgressionMarie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, et al.
Cell Reports|December 15, 2023
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer ProgressionMarie-Anne Goyette, Stéphanie Duhamel, Léo Aubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2026
Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial resultsTalia Roseshter, Anna Klemantovich, Josiane Lafleur, et al.
Cancer Research Communications|April 13, 2026
ATR and PKMYT1 inhibition re-sensitize a subset of TNBC patient-derived models to carboplatin inducing mitotic catastropheJuliet Guay, Hellen Kuasne, Catherine Chabot, et al.
Cell Metabolism|September 15, 2015
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast CancerFanny Dupuy, Sébastien Tabariès, Sylvia Andrzejewski, et al.
NAR Cancer|October 9, 2025
Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatmentNouritza Torossian, Marc Gabriel, Panagiotis Papoutsoglou, et al.
Pageof 13